Literature DB >> 2545455

Beta-adrenoceptor responses to inhaled salbutamol in normal subjects.

B J Lipworth1, D G McDevitt.   

Abstract

The aim of the present study was to quantify and compare the airways and systemic beta-adrenoceptor responses to inhaled salbutamol in normal subjects. Seven non-atopic, normal subjects were given cumulative doubling doses of inhaled salbutamol (100 micrograms to 4000 micrograms) or placebo in a single-blind cross-over design. Airways (sGaw, FEF 50%, FEF 25%), tremor, haemodynamic and metabolic responses were measured at each dose increment. There were dose-related changes in sGaw, FEF 50% and FEF 25% up to a plateau at 1.0 mg. Analysis of individual responses showed that most subjects required either 1.0 or 2.0 mg for maximum bronchodilatation, independent of the parameter of airflow. There was no correlation between maximum bronchodilatation, independent of the parameter of airflow. There was no correlation between maximum response and baseline airway calibre. In contrast to airways effects, systemic beta-adrenoceptor responses did not occur until 500 micrograms, and a ceiling in the dose-response curve was not reached. There were significant correlations between airways, tremor and haemodynamic responses, and between different metabolic variables. The intraindividual variability was greatest for tremor and sGaw, although this was small in comparison to the size of maximum change with salbutamol. The converse applied to the hypomagnesaemic response.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545455     DOI: 10.1007/BF00558154

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  Comparative effects of ephedrine on adrenergic responsiveness in normal and asthmatic subjects.

Authors:  H G Morris; S A Rusnak; J C Selner; K Barzens; J Barnes
Journal:  J Allergy Clin Immunol       Date:  1978-05       Impact factor: 10.793

2.  Subsensitivity to the bronchodilator action of albuterol produced by chronic administration.

Authors:  H S Nelson; D Raine; H C Doner; W C Posey
Journal:  Am Rev Respir Dis       Date:  1977-11

3.  Magnesium, the mimic/antagonist to calcium.

Authors:  B S Levine; J W Coburn
Journal:  N Engl J Med       Date:  1984-05-10       Impact factor: 91.245

4.  Assessing change in airway calibre--measurement of airway resistance.

Authors:  A E Tattersfield; I M Keeping
Journal:  Br J Clin Pharmacol       Date:  1979-10       Impact factor: 4.335

5.  beta-adrenergic agonist resistance in normal human airways.

Authors:  S T Holgate; C J Baldwin; A E Tattersfield
Journal:  Lancet       Date:  1977-08-20       Impact factor: 79.321

6.  Partial flow-volume curves to measure bronchodilator dos-response curves in normal humans.

Authors:  P J Barnes; H R Gribbin; D Osmanliev; N B Pride
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1981-06

Review 7.  The physiology of renal magnesium handling.

Authors:  G A Quamme; J H Dirks
Journal:  Ren Physiol       Date:  1986

8.  Systemic cardiovascular and metabolic effects associated with the inhalation of an increased dose of albuterol. Influence of mouth rinsing and gargling.

Authors:  M Küng; S W Croley; B A Phillips
Journal:  Chest       Date:  1987-03       Impact factor: 9.410

9.  The effects of cardioselective and non-selective beta-adrenoceptor blockade on the hypokalaemic and cardiovascular responses to adrenomedullary hormones in man.

Authors:  A D Struthers; J L Reid; R Whitesmith; J C Rodger
Journal:  Clin Sci (Lond)       Date:  1983-08       Impact factor: 6.124

10.  A new method for measuring airway resistance in man using a body plethysmograph: values in normal subjects and in patients with respiratory disease.

Authors:  A B DUBOIS; S Y BOTELHO; J H COMROE
Journal:  J Clin Invest       Date:  1956-03       Impact factor: 14.808

View more
  39 in total

1.  Comparison of the extrapulmonary beta2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose-inhaler and modified actuator device.

Authors:  D M Newnham; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

2.  Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects.

Authors:  N M Wheeldon; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

3.  Comparison of the efficacy and systemic effects of 4 mg and 8 mg formulations of salbutamol controlled release in patients with asthma.

Authors:  B J Lipworth; R A Clark; D P Dhillon; J B Palmer; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol.

Authors:  A Grove; B J Lipworth
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

5.  A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol.

Authors:  A Grove; B J Lipworth
Journal:  Thorax       Date:  1996-01       Impact factor: 9.139

7.  The effects of chronic dosing on the beta 1 and beta 2-adrenoceptor antagonism of betaxolol and atenolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

8.  Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients.

Authors:  D M Newnham; A Grove; D G McDevitt; B J Lipworth
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

9.  Expression of the beta 2 adrenoceptor partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone.

Authors:  A Grove; L C McFarlane; B J Lipworth
Journal:  Thorax       Date:  1995-02       Impact factor: 9.139

Review 10.  Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease.

Authors:  Mario Cazzola; Maria G Matera; Claudio F Donner
Journal:  Drugs       Date:  2005       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.